GLPwatch
[Liraglutide in the treatment of obesity : a multidisciplinary approach].
Rev Med Suisse · 2022
Last updated 2026-05-28Liraglutide is a medication approved for treating obesity in adults with a BMI of 28–35 kg/m² who also have metabolic conditions, or a BMI of 35 kg/m² or higher. Insurance coverage depends on achieving weight loss results within a set timeframe. The treatment works best when combined with lifestyle changes and requires regular monitoring by a healthcare team.
AI summary of the abstract below.
| Journal | Rev Med Suisse, 2022 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | liraglutide |
| Conditions studied | Obesity |
Abstract
Liraglutide, which has been prescribed for several years for the treatment of type 2 diabetes, is now proposed for the management of patients with BMI between 28 and 35 kg/m in the presence of metabolic comorbidity or BMI ≥ 35 kg/m. Its reimbursement by the health insurance is conditioned on weight loss results and time limited. Careful preparation of the patient and his commitment to lifestyle changes are essential for the success and good tolerance of the treatment. The introduction of this treatment requires a multidisciplinary follow-up to ensure optimal results. The place of liraglutide in the pharmacopeia of obesity, a chronic disease that requires long-term treatment, should be clarified.
Verbatim abstract via PubMed 35343119 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.